Tag Archives: AstraZeneca starts new COVID-19 prevention trials of antibody cocktail

LONDON: AstraZeneca started late-stage trials on Saturday of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months. The Phase III international clinical trial will recruit a total of 5,000 people across countries in Europe and the United States to assess the …

Read More »